PMID- 17537129
OWN - NLM
STAT- MEDLINE
DCOM- 20070810
LR  - 20181201
IS  - 1067-1927 (Print)
IS  - 1524-475X (Electronic)
IS  - 1067-1927 (Linking)
VI  - 15
IP  - 3
DP  - 2007 May-Jun
TI  - Inhibition of osteogenic differentiation of human mesenchymal stem cells.
PG  - 413-21
AB  - Mesenchymal stem cells (hMSCs) have been shown to differentiate into osteoblasts 
      that, in turn, are capable of forming tissues analogous to bone. The present 
      study was designed to investigate the inhibition of osteogenesis by hMSCs. Bone 
      marrow-derived hMSCs were treated with transforming growth factor beta-3 
      (TGFbeta3) at various doses during or after their differentiation into osteogenic 
      cells. TGFbeta3 was encapsulated in poly(DL-lactic-co-glycolic acid) (PLGA) 
      microspheres and released via controlled delivery in the osteogenic culture of 
      hMSCs and hMSC-derived osteoblasts for up to 28 days. Controlled release of 
      TGFbeta3 inhibited the osteogenic differentiation of hMSCs, as evidenced by 
      significantly reduced alkaline phosphatase activity and staining, as well as 
      decreased mineral deposition. After hMSCs had been differentiated into 
      osteoblasts, controlled release of TGFbeta3 further inhibited not only alkaline 
      phosphatase and mineral deposition but also osteocalcin expression. These 
      findings demonstrate the potential for sustained modulation of the behavior of 
      stem cells and/or stem cell-derived lineage-specific cells via controlled release 
      of growth factor(s). The attenuation of osteogenic differentiation of MSCs may 
      facilitate understanding not only the regulation and patterning of osteogenesis 
      in development but also several pathological models such as osteopetrosis, 
      craniosynostosis, and heart valve calcification.
FAU - Moioli, Eduardo K
AU  - Moioli EK
AD  - Department of Biomedical Engineering, College of Dental Medicine, Columbia 
      University, Fu Foundation School of Engineering and Applied Sciences, New York, 
      New York 10032, USA.
FAU - Hong, Liu
AU  - Hong L
FAU - Mao, Jeremy J
AU  - Mao JJ
LA  - eng
GR  - RC2 DE020767-02/DE/NIDCR NIH HHS/United States
GR  - DE15391/DE/NIDCR NIH HHS/United States
GR  - RC2 DE020767/DE/NIDCR NIH HHS/United States
GR  - R01 EB002332/EB/NIBIB NIH HHS/United States
GR  - R01 DE015391/DE/NIDCR NIH HHS/United States
GR  - EB02332/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Wound Repair Regen
JT  - Wound repair and regeneration : official publication of the Wound Healing Society 
      [and] the European Tissue Repair Society
JID - 9310939
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Transforming Growth Factor beta3)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
SB  - IM
MH  - Alkaline Phosphatase/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Kinetics
MH  - *Mesenchymal Stem Cells/cytology/drug effects/enzymology
MH  - Microspheres
MH  - Osteoblasts/drug effects
MH  - Osteogenesis/*drug effects
MH  - Polyglycolic Acid
MH  - Transforming Growth Factor beta3/administration & dosage/*pharmacology
PMC - PMC4035040
MID - NIHMS232011
EDAT- 2007/06/01 09:00
MHDA- 2007/08/11 09:00
PMCR- 2014/05/27
CRDT- 2007/06/01 09:00
PHST- 2007/06/01 09:00 [pubmed]
PHST- 2007/08/11 09:00 [medline]
PHST- 2007/06/01 09:00 [entrez]
PHST- 2014/05/27 00:00 [pmc-release]
AID - WRR244 [pii]
AID - 10.1111/j.1524-475X.2007.00244.x [doi]
PST - ppublish
SO  - Wound Repair Regen. 2007 May-Jun;15(3):413-21. doi: 
      10.1111/j.1524-475X.2007.00244.x.